Biotest AG (Biotest AG) Retained Earnings : $291.8 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biotest AG Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Biotest AG's retained earnings for the quarter that ended in Mar. 2024 was $291.8 Mil.

Biotest AG's quarterly retained earnings increased from Sep. 2023 ($214.0 Mil) to Dec. 2023 ($261.2 Mil) and increased from Dec. 2023 ($261.2 Mil) to Mar. 2024 ($291.8 Mil).

Biotest AG's annual retained earnings declined from Dec. 2021 ($136.7 Mil) to Dec. 2022 ($118.3 Mil) but then increased from Dec. 2022 ($118.3 Mil) to Dec. 2023 ($261.2 Mil).

Biotest AG Retained Earnings Historical Data

The historical data trend for Biotest AG's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG Retained Earnings Chart

Biotest AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

241.67

221.66

136.72

118.33

261.18

Biotest AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															98.18	123.62	213.98	261.18	291.85

Biotest AG Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Biotest AG (OTCPK:BIESF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Biotest AG (Biotest AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

BIO3:Germany BIO3:Austria

Address

Landsteinerstrasse 5, Dreieich, DEU, 63303

Website

https://www.biotest.com

Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.